Tag:

Janssen Biotech

Latest Headlines

Latest Headlines

J&J's Simponi Aria approved for RA as it heads for blockbuster stratosphere

The FDA has approved Simponi in combination with methotrexate to treat moderately to severely active rheumatoid arthritis. The company points out that an estimated 1.3 million Americans and more than 23.5 million people worldwide suffer from RA. 

J&J releases more Doxil to the market

Johnson & Johnson and the FDA sprang into action in 2011 when J&J's popular chemo drug Doxil became hard to get because of problems with the contract manufacturer. But it also figured out a process by which it could have it manufactured at one plant and finished at another.

J&J fights $327M Risperdal verdict, saying no one was harmed

South Carolina Circuit Judge Roger Couch took a particularly creative approach when he levied a $327 million penalty against Johnson & Johnson in the state's Risperdal case.

Zytiga data presents new threat to Provenge

Johnson & Johnson's ($JNJ) prostate cancer pill Zytiga has shown it's effective in patients who haven't yet received chemotherapy.

UPDATED: J&J said to settle TX Risperdal case for $158M

Johnson & Johnson ($JNJ) says it will pay $158 million to settle a high-profile Texas suit alleging that it defrauded the state by misleading doctors about its antipsychotic drug Risperdal.

Witness: J&J memo urged off-label Risperdal push

Texas officials unveiled an internal Johnson & Johnson ($JNJ) memo in court yesterday as attorneys seek to prove the company's Risperdal marketing overstepped its bounds, cheating the state out

Metamark signs potential $365M deal with J&J unit

Metamark Genetics has entered an agreement with Janssen Biotech, a unit of Johnson & Johnson ($JNJ), to identify and characterize proprietary cancer targets that play a causal role in promoting

J&J nabs Pharmacyclics cancer candidate in $975M deal

Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are